Related Experiment Video

Updated: Jun 19, 2025

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.3K

KRAS Mutation Subtypes and Their Association with Other Driver Mutations in Oncogenic Pathways

Koushik Mondal1,2, Mahesh Kumar Posa3, Revathi P Shenoy4

  • 1Division of Basic & Translational Research, Saroj Gupta Cancer Centre & Research Institute, MG Road, Kolkata 700063, West Bengal, India.

Cells
|July 26, 2024
PubMed

Insights

KRAS mutations are key drivers of cancer. This study reveals common KRAS variants co-occur with other mutations like TP53, PIK3CA, and APC, impacting cancer progression and treatment.

Area of Science:

  • Oncology
  • Genetics
  • Bioinformatics

Background:

  • KRAS mutations are crucial oncogenic drivers.
  • Understanding co-occurrence with other driver mutations is limited.
  • KRAS interactions influence cancer hallmarks.

Purpose of the Study:

  • To investigate KRAS co-mutation patterns.
  • To explore correlations between KRAS and other driver mutations.
  • To assess prognostic and predictive implications.

Main Methods:

  • Utilized cBioPortal, TCGA, UALCAN, and UniProt databases.
  • Analyzed co-occurrence of KRAS variants with other mutations.
  • Examined transcript-level correlations.

Main Results:

  • G12D and G12V KRAS variants co-occur with TP53 in PAAD and CRAD.
  • G12C and G12V KRAS variants co-occur with LUAD.
  • KRAS shows positive transcript-level correlation with PIK3CA and APC in CRAD.

Conclusions:

  • KRAS co-mutations with TP53, PIK3CA, and APC are prevalent in specific cancers.
  • These co-mutations may influence cancer signaling pathways.
  • Identifying co-mutation patterns has significant therapeutic implications.
Keywords:
KRAScBioPortaldomainmutationpredictive responseprognostic responsesignaling pathwaytherapeutic strategy

More Related Videos

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells10:13

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells

Published on: July 3, 2013

11.1K
Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

6.0K

Related Concept Videos

The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.2K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.8K
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
11.8K
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
3.9K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K